Login

Nathaniel Swanson

ORCID: 0000-0003-1017-9086
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5051987166
Research Areas
  • Virus-based gene therapy research
  • Membrane Separation Technologies
  • Microfluidic and Bio-sensing Technologies
  • Protein purification and stability
  • CRISPR and Genetic Engineering
  • CAR-T cell therapy research
 Understanding Loss of Soluble High Molecular Weight Species during Filtration of Low Concentration Therapeutic Monoclonal Antibodies
OPENALEX - Publications 
Arthur J. Schick Yi Li Philippe Lam Preston Pallante Nathaniel Swanson and 1 more Jacqueline Y. Tyler

10.1016/j.xphs.2021.02.015 article EN Journal of Pharmaceutical Sciences 2021-02-21
 1223 Non-viral targeted knock-in of a KRAS G12D specific TCR, CD8αβ, and chimeric cytokine receptor in theTRAClocus outperforms lentiviral-based engineering of T cells
OPENALEX - Publications 
Santosh Narayan Allison P. Drain Nathaniel Swanson Nicholas Rouillard Tyler Warner and 26 more Nicole Danek Ken Gareau Cheryl Black James T. Parsons A. W. Thomas Jinsheng Liang Luhua Shen Tanya Tetrault Vincent Nguyen Iqraa Priyata Sarah Vidyasagar Joshua Francis Xingyue He Patrick Browne Rebecca Lamothe Meghan D. Storlie Gregory J. Cost Thomas M. Schmitt Philip D. Greenberg Smita S. Chandran Christopher A. Klebanoff Ankit Gupta Damien Hallet Gary Shapiro Kim Nguyen Loı̈c Vincent

<h3>Background</h3> The AFNT-212 cell therapy consists of autologous CD8+ and CD4+ T cells expressing 1) a Cell Receptor (TCR) specific for the prevalent oncogenic driver KRAS G12D mutation presented by HLA-A*11:01, 2) chimeric cytokine receptor, 3) CD8α/β coreceptor enabling coordinated CD4+/CD8+ anti-tumor response to promote activity while minimizing exhaustion. While viral vectors, including lentivirus (LVV), have been standard modality deliver transgenes therapies, they are limited...

10.1136/jitc-2023-sitc2023.1223 article EN cc-by-nc Regular and Young Investigator Award Abstracts 2023-10-31
Coming Soon ...